Evidence map›Paper›PMID 32555420›Full record

ReviewNature reviews. Clinical oncology2020

Personalized early detection and prevention of breast cancer: ENVISION consensus statement.

Nora Pashayan, Antonis C Antoniou, Urska Ivanus, Laura J Esserman, Douglas F Easton, David French, Gaby Sroczynski, Per Hall, Jack Cuzick, D Gareth Evans and 24 more

Erratum issuedAbstract readConsensus StatementReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nature reviews. Clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 234 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
234citing papers in PubMed, 12 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

234 citing papers in PubMed, 12 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Trial
  15. Trial
  16. Effects of a 4Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024
    Trial
  17. Trial
  18. Trial
  19. Trial
  20. Article

174 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

34 authors.

Nora PashayanDepartment of Applied Health Research, Institute of Epidemiology and Healthcare, University College London, London, UK.ORCID http://orcid.org/0000-0003-0843-2468
Antonis C AntoniouDepartment of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Urska IvanusEpidemiology and Cancer Registry, Institute of Oncology Ljubljana, Ljubljana, Slovenia.ORCID http://orcid.org/0000-0002-7909-522X
Laura J EssermanCarol Franc Buck Breast Care Center, University of California, San Francisco, CA, USA.
Douglas F EastonDepartment of Public Health and Primary Care, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0003-2444-3247
David FrenchDivision of Psychology & Mental Health, School of Health Sciences, University of Manchester, Manchester, UK.ORCID http://orcid.org/0000-0002-7663-7804
Gaby SroczynskiDepartment of Public Health, Health Services Research and Health Technology Assessment, Institute of Public Health, Medical Decision Making and Health Technology Assessment, UMIT-University for Health Sciences, Medical Informatics and Technology, Hall in Tirol, Austria.
Per HallDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Jack CuzickWolfson Institute of Preventive Medicine, Barts and The London, Centre for Cancer Prevention, Queen Mary University of London, London, UK.
D Gareth EvansDivision of Evolution and Genomic Sciences, University of Manchester, Manchester, UK.
Jacques SimardGenomics Center, CHU de Québec - Université Laval Research Center, Québec, Canada.ORCID http://orcid.org/0000-0001-6906-3390
Montserrat Garcia-ClosasDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Rita SchmutzlerCenter of Family Breast and Ovarian Cancer, University Hospital Cologne, Cologne, Germany.
Odette WegwarthMax Planck Institute for Human Development, Center for Adaptive Rationality, Harding Center for Risk Literacy, Berlin, Germany.
Paul PharoahDepartment of Public Health and Primary Care, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0001-8494-732X
Sowmiya MoorthiePHG Foundation, Cambridge, UK.
Sandrine De MontgolfierIRIS Institute for Interdisciplinary Research on Social Issues, Paris, France.ORCID http://orcid.org/0000-0002-4216-9379
Camille BaronUnicancer, Paris, France.
Zdenko HercegEpigenetic Group, International Agency for Research on Cancer (IARC), WHO, Lyon, France.ORCID http://orcid.org/0000-0003-4109-3154
Clare TurnbullDivision of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
Corinne BalleyguierDepartment Medical Imaging, Institut Gustave Roussy, Villejuif, France.
Paolo Giorgi RossiEpidemiology Unit, Azienda USL di Reggio Emilia - IRCCS, Reggio Emilia, Italy.
Jelle WesselingDivision of Molecular Pathology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.
David RitchieFaculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.ORCID http://orcid.org/0000-0003-4816-113X
Marc TischkowitzDepartment of Medical Genetics, National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK.
Mireille BroedersDepartment for Health Evidence, Radboud University Medical Center, Nijmegen, Netherlands.
Dan ReiselDepartment of Women's Cancer, Institute for Women's Health, University College London, London, UK.
Andres MetspaluThe Estonian Genome Center, Institute of Genomics, University of Tartu, Tartu, Estonia.ORCID http://orcid.org/0000-0002-3718-796X
Thomas CallenderDepartment of Applied Health Research, Institute of Epidemiology and Healthcare, University College London, London, UK.ORCID http://orcid.org/0000-0001-8440-9433
Harry de KoningDepartment of Public Health, Erasmus MC, Rotterdam, Netherlands.ORCID http://orcid.org/0000-0003-4682-3646
Peter DevileeDepartment of Human Genetics, Department of Pathology, Leiden University Medical Centre, Leiden, Netherlands.
Suzette DelalogeBreast Cancer Department, Gustave Roussy Institute, Paris, France.ORCID http://orcid.org/0000-0003-2106-9165
Marjanka K SchmidtDivision of Molecular Pathology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.ORCID http://orcid.org/0000-0002-2228-429X
Martin WidschwendterDepartment of Women's Cancer, Institute for Women's Health, University College London, London, UK. M.Widschwendter@ucl.ac.uk.ORCID http://orcid.org/0000-0002-7778-8380

Funding

Cancer Research UK 16891Cancer Research UK 20861Cancer Research UK 27223World Health Organization 001
6 · The paper itself

Abstract

The European Collaborative on Personalized Early Detection and Prevention of Breast Cancer (ENVISION) brings together several international research consortia working on different aspects of the personalized early detection and prevention of breast cancer. In a consensus conference held in 2019, the members of this network identified research areas requiring development to enable evidence-based personalized interventions that might improve the benefits and reduce the harms of existing breast cancer screening and prevention programmes. The priority areas identified were: 1) breast cancer subtype-specific risk assessment tools applicable to women of all ancestries; 2) intermediate surrogate markers of response to preventive measures; 3) novel non-surgical preventive measures to reduce the incidence of breast cancer of poor prognosis; and 4) hybrid effectiveness-implementation research combined with modelling studies to evaluate the long-term population outcomes of risk-based early detection strategies. The implementation of such programmes would require health-care systems to be open to learning and adapting, the engagement of a diverse range of stakeholders and tailoring to societal norms and values, while also addressing the ethical and legal issues. In this Consensus Statement, we discuss the current state of breast cancer risk prediction, risk-stratified prevention and early detection strategies, and their implementation. Throughout, we highlight priorities for advancing each of these areas.

Indexed as

Breast NeoplasmsConsensusEarly Detection of CancerEvidence-Based MedicineFemaleGenetic Predisposition to DiseaseHumansMass ScreeningPrecision Medicine

Identifiers

PMID32555420
PMCPMC7567644

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.